AFX:XETRA-Carl Zeiss Meditec AG (EUR)

COMMON STOCK | Medical Instruments & Supplies | XETRA

Last Closing Price

EUR 132.95

Change

-0.35 (-0.26)%

Market Cap

EUR 11.92B

Volume

0.03M

Avg Analyst Target

EUR 169.60 (+27.57%)

Avg User Target

EUR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AFX Stock Forecast & Price:
Based on the Carl Zeiss Meditec AG stock forecasts from 4 analysts, the average analyst target price for Carl Zeiss Meditec AG is EUR 169.60 over the next 12 months. Carl Zeiss Meditec AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Carl Zeiss Meditec AG is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Carl Zeiss Meditec AG’s stock price was EUR 132.95. Carl Zeiss Meditec AG’s stock price has changed by +0.23% over the past week, +9.38% over the past month and -23.50% over the last year.

About Carl Zeiss Meditec AG (AFX:XETRA)

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers products and solutions for the diagnosi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTL:XETRA Baxter International Inc

N/A

EUR29.61B 30.31 16.91
SRT:XETRA Sartorius AG VZO O.N.

-2.50 (-0.76%)

EUR24.04B 41.47 20.66
SRT3:XETRA Sartorius Aktiengesellschaft

-2.50 (-0.67%)

EUR24.04B 48.60 20.25
FIE:XETRA Fielmann Aktiengesellschaft

-2.38 (-6.32%)

EUR2.96B 26.51 18.63
GXI:XETRA Gerresheimer AG

-0.90 (-1.30%)

EUR2.17B 23.99 10.13

ETFs Containing AFX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -28.08% 80% B- 15% F
Dividend Return 0.49% 60% D- 9% F
Total Return -27.59% 80% B- 14% F
Trailing 12 Months  
Capital Gain -23.22% 80% B- 18% F
Dividend Return 0.52% 60% D- 9% F
Total Return -22.70% 80% B- 18% F
Trailing 5 Years  
Capital Gain 170.75% 60% D- 97% A+
Dividend Return 5.09% 50% F 28% F
Total Return 175.84% 60% D- 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 27.75% 60% D- 93% A
Dividend Return 0.51% 60% D- 51% F
Total Return 28.26% 60% D- 93% A
Risk Return Profile  
Volatility (Standard Deviation) 35.95% 60% D- 19% F
Risk Adjusted Return 78.62% 60% D- 86% B
Market Capitalization 11.92B 60% D- 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 48.65 20% F 16% F
Price/Book Ratio 6.74 60% D- 11% F
Price / Cash Flow Ratio 32.87 20% F 7% F
EV/EBITDA 33.82 20% F 4% F
Management Effectiveness  
Return on Equity 16.04% 60% D- 65% D
Return on Invested Capital 16.62% 40% F 80% B-
Return on Assets 10.21% 60% D- 88% B+
Debt to Equity Ratio 4.61% 80% B- 87% B+
Technical Ratios  
Dividend Yield 0.69% 60% D- 10% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.81 40% F 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.